Aim:to study the dynamic of echocardiographic parameters in patients with acute coronary syndrome associated with anxiety and depressive disorders during the therapy by innovative Russian drug containing release-active antibodies to the brain-specific protein S-100 (Tenoten) in-hospital and during six months of treatment.Material and Methods. 54 patients with acute coronary syndrome associated with anxiety and depressive disorders were randomized into 2 groups: patients of group 1 were administered with anti-anxiety medicament Tenoten, 6 tablets per day in addition to the therapy for acute coronary syndrome; group 2 received placebo. All patients underwent echocardiography at inpatient and outpatient stages six months after randomization.Results. Clinically significant anxiety and subclinical depression were detected in patients of both study groups. The intake of anti-anxiety drug Tenoten for six months contributed to anxiety reduction, myocardial contractility improvement, and a decrease in the left ventricular volume indices. Negative changes were observed in comparison group: a decrease in the left ventricular ejection fraction, increase in volume indices, and decline in the left ventricular relaxation.Conclusion. Administration of Tenoten at a dose of six tablets per day to patients with acute coronary syndrome in combination with affective disorders resulted not only in improvement of a mental status, but it also contributed to suppression of the left ventricular remodeling processes.
DOES THE CORRECTION OF THE ANXIETY-DEPRESSIVE DISORDERS INFLUENCE ON THE PROCESSES OF THE LEFT VENTRICULAR REMODELING IN PATIENTS WITH ACUTE CORONARY SYNDROME?